Human Growth Hormone

Human growth hormone, clinically supplied as recombinant somatropin, is a regulated prescription biologic with well-defined approved indications and substantial clinical literature. It is distinct from unapproved secretagogues, fragments, or research peptides. In approved care, somatropin is used for specific pediatric growth disorders and for adults with confirmed growth hormone deficiency under specialist supervision. Adult growth hormone deficiency guidelines emphasize biochemical diagnosis, individualized dosing, IGF-1 monitoring, and risk-benefit assessment. Randomized trials in adults with confirmed deficiency show the most consistent effects on body composition, including increased lean mass and reduced fat mass, while effects on strength, quality of life, lipids, and bone outcomes vary.

Confirmed GH Deficiency

In confirmed adult growth hormone deficiency, replacement therapy can improve body composition, typically increasing lean body mass and reducing fat mass ^[1][2][3].

Guideline and Label Context

Endocrine Society guidance supports GH replacement only after appropriate diagnostic evaluation and individualized risk assessment, while FDA-regulated somatropin labels define approved indications ^[1][4].

Evidence Boundary

HGH should not be presented as an anti-aging, athletic, or cosmetic body-composition product.

Serious Contraindications

Somatropin is contraindicated in acute critical illness after major surgery, multiple trauma, or acute respiratory failure because increased mortality was observed with pharmacologic dosing in non-GH-deficient critically ill adults ^[4].

Monitoring and Adverse Effects

Labels also warn about active malignancy, severe diabetic retinopathy, glucose intolerance/diabetes, intracranial hypertension, fluid retention, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, and pancreatitis ^[4].